Macrophage depletion increases target specificity of bone‐targeted nanoparticles

2021 ◽  
Author(s):  
Marian A. Ackun‐Farmmer ◽  
Baixue Xiao ◽  
Maureen R. Newman ◽  
Danielle S.W. Benoit
Keyword(s):  
Target Specificity ◽  
Targeted Nanoparticles ◽  
Macrophage Depletion

Accessing Targeted Nanoparticles to the Brain: The Vascular Route

2014 ◽  
Vol 21 (36) ◽  
pp. 4092-4099 ◽  
Author(s):  
A. Burkhart ◽  
M. Azizi ◽  
M.S. Thomsen ◽  
L.B. Thomsen ◽  
T. Moos
Keyword(s):  
Targeted Nanoparticles ◽  
The Brain

Theranostic Potential of Targeted Nanoparticles for Brain Cancer

2017 ◽  
Vol 17 (18) ◽  
Author(s):  
Ajita Bhatt ◽  
Ekta Gurnany ◽  
Anuj Modi ◽  
Arvind Gulbake ◽  
Aviral Jain
Keyword(s):  
Brain Cancer ◽  
Targeted Nanoparticles

Encapsulation of Imatinib in Targeted KIT-5 Nanoparticles for Reducing its Cardiotoxicity and Hepatotoxicity

2020 ◽  
Vol 20 (16) ◽  
pp. 1966-1980
Author(s):  
Jaleh Varshosaz ◽  
Saeedeh Fardshouraki ◽  
Mina Mirian ◽  
Leila Safaeian ◽  
Setareh Jandaghian ◽  
...  
Keyword(s):  
Controlled Release ◽  
Side Effects ◽  
Kinase Inhibitor ◽  
Lymphoblastic Leukemia ◽  
Drug Carrier ◽  
Free Drug ◽  
Jurkat Cells ◽  
Targeted Nanoparticles ◽  
Inhibitor Drug ◽  
Histopathological Results

Background: Using imatinib, a tyrosine kinase inhibitor drug used in lymphoblastic leukemia, has always had limitations due to its cardiotoxicity and hepatotoxicity side effects. The objective of this study is to develop a target-oriented drug carrier to minimize these adverse effects by the controlled release of the drug. Methods: KIT-5 nanoparticles were functionalized with 3-aminopropyltriethoxysilane and conjugated to rituximab as the targeting agent for the CD20 positive receptors of the B-cells. Then they were loaded with imatinib and their physical properties were characterized. The cell cytotoxicity of the nanoparticles was studied by MTT assay in Ramos (CD20 positive) and Jurkat cell lines (CD20 negative) and their cellular uptake was shown by fluorescence microscope. Wistar rats received an intraperitoneal injection of 50 mg/kg of the free drug or targeted nanoparticles for 21 days. Then the level of aspartate Aminotransferase (AST), alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP) and Lactate Dehydrogenase (LDH) were measured in serum of animals. The cardiotoxicity and hepatotoxicity of the drug were also studied by hematoxylin and eosin staining of the tissues. Results: The targeted nanoparticles of imatinib showed to be more cytotoxic to Ramos cells rather than Jurkat cells. The results of the biochemical analysis displayed a significant reduction in AST, ALT, ALP, and LDH levels in animals treated with targeted nanoparticles, compared to the free drug group. By comparison with the free imatinib, histopathological results represented less cardiotoxicity and hepatotoxicity in the animals, which received the drug through the current designed delivery system. Conclusion: The obtained results confirmed that the rituximab targeted KIT-5 nanoparticles are promising in the controlled release of imatinib and could decrease its cardiotoxicity and hepatotoxicity side effects.

Macrophage depletion alters the blood–nerve barrier without affecting Schwann cell function after neural injury

2007 ◽  
Vol 85 (4) ◽  
pp. 766-777 ◽  
Author(s):  
Michael Gray ◽  
Winnie Palispis ◽  
Phillip G. Popovich ◽  
Nico van Rooijen ◽  
Ranjan Gupta
Keyword(s):  
Schwann Cell ◽  
Cell Function ◽  
Neural Injury ◽  
Macrophage Depletion

A promising targeting system to enrich irinotecan antitumor efficacy: Folic acid targeted nanoparticles

2021 ◽  
Vol 63 ◽  
pp. 102543
Author(s):  
Borhaneh Hasan-Nasab ◽  
Pedram Ebrahimnejad ◽  
Pouneh Ebrahimi ◽  
Faezeh Sharifi ◽  
Maryam Salili ◽  
...  
Keyword(s):  
Folic Acid ◽  
Antitumor Efficacy ◽  
Targeted Nanoparticles
Sign in / Sign up

Export Citation Format

Share Document